Alzheimer's registry for treatment and diagnosis
Part of Brain & nervous system, Mental health clinical trials.
This registry collects information from people with mild cognitive impairment or dementia due to Alzheimer's disease who are being treated with new FDA-approved therapies. The goal is to track how these treatments work in everyday medical practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with mild cognitive impairment or dementia, and Alzheimer's disease is likely a contributing cause.
- You are either being considered for, about to start, or have already started a new FDA-approved Alzheimer's treatment.
- Your decision to start treatment was made by your doctor as part of your regular care, not because of this registry.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information from people with mild cognitive impairment or Alzheimer's disease who are starting a new medication. It helps researchers learn more about these conditions and their treatments over time.
This study creates a registry for people who are using newly approved Alzheimer's medications. It tracks how these treatments work over time and may help researchers learn more about diagnosing and treating Alzheimer's.
This is a research registry that helps doctors compare how different memory and Alzheimer’s risk groups change over time. It may help researchers learn which people are more likely to develop Alzheimer’s and how to better track early changes.
This study registry collects health and brain-testing information for people with mild cognitive impairment or early Alzheimer’s dementia. It may help researchers better understand early Alzheimer disease and plan future treatments.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.